PAXAFE 首席商务官谈将人工智能嵌入制药供应链：GxP 环境下的风险与人工监督
Embedding Artificial Intelligence within Pharma Supply Chains
PAXAFE 首席商务官 Mark Talens 指出，许多制药供应链方案将 AI 叠加在遗留软件之上，而非针对特定用途设计，可能带来数据碎片化、幻觉及 GxP 环境下审计性有限等风险。他提出应以端到端方式实时整合天气、政治事件、路线中断等多源高质量数据，支持产品从包装到患者手中的冷链全程。Talens 强调需对 AI 进行审计并保持人工监督，以在 AI 自动化推进中建立信任。
Feature|Videos|October 7, 2026
Key Takeaways
- Identify the risks of layering AI onto legacy supply chain systems, including data fragmentation, hallucinations, and limited auditability in GxP environments.
- Describe how end-to-end contextualization of internal and syndicated data supports real-time decisions across the pharmaceutical cold chain.
- Detail the progression of AI automation and the role of human oversight in building trust in AI-driven decisions.
SHOW MORE
Sponsored by PAXAFE
Artificial intelligence (AI) is advancing quickly, yet many pharmaceutical supply chain solutions layer AI onto legacy software rather than designing one for a specific purpose. This approach can complicate decisions in an industry that requires good practice (GxP) compliance. Drawing on supply chain expertise, Mark Talens, Chief Commercial Officer at PAXAFE, highlights the consequences of this persistent fragmentation problem. He outlines guardrails for AI adoption, clear expectations for what AI should deliver, and defined limits on what AI may act on rather than only recommend. For example, using an end-to-end approach that contextualizes multiple high-quality data sources in real time—weather, political events, route disruptions—can support a product as it moves across the cold chain from packaging to the hands of a patient. Talens further emphasizes the need to audit AI and keep human oversight at the forefront. Doing so builds a foundation of trust as AI solutions progression and provides more automation across the supply chain.
Related to this article
来源：Pharmaceutical Commerce · pharmaceuticalcommerce.com